News & Updates

Ferric carboxymaltose (FCM) is as good as ferric derisomaltose (FDI) in the treatment of iron-deficiency anaemia, although FCM leads to a higher frequency of hypophosphatemia, according to data from the PHOSPHARE-IBD study.

First-line rucaparib maintenance therapy extends progression-free survival (PFS) in patients with ovarian, fallopian tube, or primary peritoneal cancer, according to results of the phase III ATHENA-MONO trial presented at the ESMO Gynaecological Cancers Conference 2022.

In the phase III STRATUM* trial, the investigational PDE4** inhibitor roflumilast improved multiple symptoms of moderate-to-severe seborrheic dermatitis (SD).

In patients with unresectable RAS and BRAF wildtype metastatic colorectal cancer (mCRC), a modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN*) treatment strategy in the first-line setting did not improve objective response rate (ORR) compared with FOLFOX plus panitumumab (mFOLFOX6/PAN**), results of the phase III TRIPLETE study showed.

Boosting with an mRNA vaccine yields significant protection against severe COVID-19 and may keep people out of the hospital for up to 6 months, as shown in a Singapore study.